Inappropriate Sinus Tachycardia (IST) is a chronic medical condition with a wide variety of clinical presentations making it, sometimes, very insidious at the time of the diagnosis. Several therapeutic options, including, pharmacotherapy, cardiac rehabilitation, and modification or ablation of the sinus node, have been proposed for the management of IST, but because of the complexity and lack of understanding of pathophysiology, it can be difficult to manage, despite the numerous treatment options currently available. The purpose of this review is to analyze the treatment for IST, focusing on the role of newer therapy and the potential benefits in the management of this cardiac rhythm disturbance.
INTRODUCTION
Inappropriate Sinus Tachycardia (IST) was initially described by Codvelle and Boucher 1 in 1939, as a case report of a young adult male patient with a resting heart rate of 160 bpm for more than 2 years, without functional disorders. Currently, IST is defined as a sinus heart rate .100 bpm at rest, with a mean 24-hour heart rate .90 bpm, not due to primary underlying causes, and is associated with distressing symptoms of palpitations, which are nonparoxysmal. 2 IST is identified to have no abnormalities on EKG, meaning that there is no change with the P wave morphology, and the endocardial activation demonstrates an undistinguishable pattern to the sinus rhythm. 3 The underlying mechanisms of IST are not well understood; however, a relationship between IST and circulating antibeta-adrenergic receptor antibodies that provoke a persistent increase in cAMP production has been postulated. 4 Hence, a primary autonomic disorder with an increase in sympathetic activity and enhanced sinus node beta-adrenergic sensitivity are seen in IST. 5 The clinical presentation of patients with IST can vary because of the diversity of its multiple symptoms, which include intermittent palpitations, dyspnea, dizziness, lightheadedness, presyncope, syncope, chest pain, myalgia, and fatigue. 6 Associated psychological and emotional problems can also be seen, but no relationship with IST has been identified. 7 See Table 1 . Using a criteria of a resting heart rate .100 bpm and an average heart rate of .90 bpm on 24-hour Holter monitoring, Still et al estimated the prevalence of IST in a population of middle-aged men and women. The IST prevalence corresponded to 1.2% (7 of 604 patients), 8 which included both symptomatic and asymptomatic patients. IST has also been reported in older populations. 9 Although, IST is believed to be a chronic condition, the long-term complications are few. IST has been associated with tachycardia-induced cardiomyopathy in isolated cases, 10, 11 and no mortality has been yet reported.
IST is a medical entity that should be diagnosed by exclusion, medical history, and physical examination and should be assessed thoroughly, aiming to the potential causes of sinus tachycardia. Thus, thyroid disease, medications, hypovolemia, panic attacks, anxiety, and substance abuse should be ruled out. A 12-lead EKG is useful for recording tachycardia and defining sinus rhythms, which helps to differentiate 1 IST from other disorders of the sinus node and additional atrial tachyarrhythmias. Twenty-four hour Holter monitoring can be useful for confirming the diagnosis. 2 In summary, the diagnosis of IST should meet the following clinical and electrophysiological criteria 3 :
1. Sinus heart rate .100 bpm at rest. 2. Symptoms are not paroxysmal. 3. Intact P wave morphology. 4 . Endocardial activation demonstrates an undistinguishable pattern to the sinus rhythm. 5. Secondary causes of tachycardia should be ruled out.
TREATMENT
The management of IST consists of controlling 2 variables: (1) symptoms and (2) heart rate; this could be challenging because the syndrome itself is unclear. One variable could be independent from the other, meaning that controlling the heart rate does not necessarily imply the suppression of symptoms, and vice versa. The management of asymptomatic patients with IST is under debate; since controlling the heart rate in this group might be counterproductive and more damaging than the syndrome itself. 7 Many treatment options have been suggested for patients with IST, including pharmacotherapy, cardiac rehabilitation, and occasionally radiofrequency modification of the sinus node. 12 Among the pharmacotherapy options, b-blockers and nondihydropyridine calcium-channel blockers have been the backbone of medical therapy for IST. 3 Although, they are frequently not well tolerated due to their side effects, 13, 14 which are common in young population, and most of the time are unrelated to heart rate reduction. Although no randomized, double-blinded, placebocontrolled clinical trials exist, b-blockers may be useful and beneficial, and therefore, should be prescribed as first-line therapy in most cases of patients with IST.
The recent introduction of ivabradine, 15,16 a selective I f (pacemaker) current inhibitor in the sinoatrial node, 17 has provided researchers the opportunity to assess its properties on cardiac cronotropism in the management of IST. By inhibiting the I f (pacemaker) current, ivabradine reduces the heart rate without affecting or influencing in blood pressure or left ventricular systolic function, 18 hence, ivabradine promises a better tolerability during the treatment of IST. Ptaszynski et al studied the effectiveness of ivabradine monotherapy on 20 patients affected by IST, who were resistant to previous administered therapy using b-blockers or verapamil. During the study they observed a significant decrease of resting heart rate in both groups treated with metoprolol and ivabradine, respectively, compared with the baseline (92.8 vs. 90.2 vs. 114.3 bpm; P , 0.001). 13 Ivabradine was very well tolerated; whereas, in 10 patients on metoprolol, hypotension or bradycardia occurred and dose reduction was required. The efficacy of ivabradine, in comparison to the maximally tolerated dose of metoprolol succinate, was greater in reducing cardiac chronotropic properties, and subsequently, relieving symptoms of IST during daily activity or exercise.
Cappato et al, evaluated the role of ivabradine in the treatment of IST, when this condition is refractory to b-blockers and nondihydropyridine calcium-channel blockers. They assessed a prospective, randomized, placebo-controlled, crossover study demonstrating that in 21 patients, who were randomized to ivabradine versus placebo and followed the routine for a period of 6 weeks, ivabradine eliminated 70% of the IST-related symptoms after 4 weeks of oral administration of the drug. A complete elimination of symptoms can be expected to occur in 50% of patients with a significant decrease in heart rate at various physiological conditions such as resting, changes in position (after standing), during daytime and nighttime, during 24-hour Holter monitoring, and even at the maximum stress test. 19 Ivabradine has shown to be effective also in patients with IST after radiofrequency catheter ablation of atrioventricular node, being a treatment option to reduce heart rate and symptoms when b-blockers and nondihydropyridine calcium-channel blockers are not well tolerated. 20 Currently, there are no head-to-head randomized clinical data to support the use of ivabradine as firstline monotherapy in patients with symptomatic IST. Nonetheless, in June 2016, the prospective study titled: "Comparison of ivabradine and beta-blockers administration in the treatment of inappropriate sinus tachycardia" (CIBIST), is expected to be completed. It focuses on the effectiveness and safety of first-line monotherapy with ivabradine (5-7.5 mg twice-daily) when compared to that with the b-blocker bisoprolol (5-10 mg once-daily), in the treatment of IST. The role of ablation or modification of the sinus node is not well defined, however, it strives to modify the sinus node and decrease or eliminate sympathetic inputs. Clinical evidence is scarce and debated, mostly because of the small number of patients who have undergone these procedures and the absence of a control group. The criteria for ideal approach of these invasive techniques, which include modification or ablation, open chest versus conventional intravascular access, and mapping methods, has not been met by the consensus. Nevertheless, the short-term success rates are equitably noble, but the outcomes were noted not to be sustained in the long term. Also, there is a high rate of recurrence and persistency of partial alleviation of symptoms. Complications, including requirements for permanent pacing, transient or permanent phrenic nerve paralysis, and transient superior vena cava syndrome, are significant and have to be taken into account before making any decision to proceed with the patient because of their aggressive nature that might, in some cases, overweigh any potential benefit regardless of the severity of IST. 2, 7, 21, 22 Therefore, it is not recommendable to practice these techniques as part of routine care. See Table 2 .
CONCLUSIONS
Pharmacotherapy is preferred at the time of management of IST. Ivabradine, which is the only selective I f (pacemaker) current inhibitor presently available, promises to be more tolerable than b-blockers and nondihydropyridine calcium-channel blockers. Its efficacy has been studied, and it has demonstrated to be effective when the mainstay of treatment of IST could not be tolerated. Clinical data to support ivabradine for firstline monotherapy is not available; therefore, b-blockers and nondihydropyridine calcium-channel blockers should be prescribed as first-line therapy in most patients with IST. Invasive procedures have been shown to be effective in the short-term outcome; however, a high rate of recurrence has been noted in the long-term outcome.
The complications of such techniques should be considered beforehand because of their complexity and severity, and the protocol of approach should be established.
